Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2026)

Denali Therapeutics (DNLI) has 10 years of Total Current Liabilities data on file, last reported at $110.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 19.9% year-over-year to $110.2 million in Q1 2026; TTM through Mar 2026 was $110.2 million, a 19.9% increase from a year earlier, with the FY2025 full-year figure at $98.4 million, down 3.77% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $110.2 million, up from $98.4 million in the prior quarter.
• Over the last five years, Total Current Liabilities for DNLI reached as high as $391.1 million in Q1 2023 and fell as low as $69.4 million in Q2 2023.
• Historically, Total Current Liabilities has averaged $167.7 million across 5 years, with a median of $91.9 million in 2025.
• Across the five-year window, Total Current Liabilities soared 577.2% in 2022 and plunged 80.26% in 2023, its largest moves.
• Year by year, Total Current Liabilities stood at $363.9 million in 2022, then tumbled by 78.57% to $78.0 million in 2023, then soared by 31.07% to $102.2 million in 2024, then fell by 3.77% to $98.4 million in 2025, then climbed by 12.0% to $110.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $110.2 million in Q1 2026, $98.4 million in Q4 2025, and $90.1 million in Q3 2025.